Logo
Linkedin
Linkedin

China Biotech: Innovation, Opportunity, and a New ETF

  • ETFs

ETF innovation is truly staggering.  After hosting ETF Prime for 7+ years and visiting weekly with the brightest minds the industry has to offer, I can only compare the sheer level of talent and entrepreneurial spirit to Silicon Valley.  With so many unique and interesting ETF stories, I thought it would be fun to occasionally venture down the rabbit hole and delve deeper into areas I personally find fascinating.

This week, Brad Loncar, a Kansas City native and biotech investing expert, takes us into the world of China biotech.  While Brad would never say this, I consider Brad among the smartest biotech investors I have ever met.  Brad developed the indexes behind the Loncar Cancer Immunotherapy ETF (CNCR) and the recently launched China BioPharma ETF (CHNA).  If you have any interest in biotech whatsoever, I think you’ll find this conversation insightful.  Hope you enjoy!

 

Picture of Nate Geraci
Nate Geraci

Nate is President of NovaDius Wealth Management, a registered investment advisor providing clients with comprehensive financial planning and portfolio management. Previously, Nate helped launch The ETF Store, an investment advisory firm specializing in Exchange Traded Funds.

He is the creator and host of the weekly podcast ETF Prime, which Bloomberg has called one of the “most helpful plain-English resources for investors who want to demystify exchange-traded funds”.

He is creator and Host of Crypto Prime, which features interviews with top experts from around the world on bitcoin, crypto, NFTs, and the entire web3 ecosystem.

Nate is also Co-Founder of The ETF Institute, the first and only independent organization providing ETF industry professionals and financial advisors with certification, education, and training pertaining to ETFs.

Related Posts

Skip to content